Skip to main content
UniHealth

Doctor search

Darius Mohammad Moshfeghi, MD

Ophthalmology · Palo Alto

NPI 1386702819

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Moshfeghi’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026

California Medical Board record

Licence A78163 · Current

Licensed to practise in California · since 2002 · expires 2028-03-31 · Tulane University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Virginia 0101277785Physician · since 2023 · expires 2028-03-31Told the state board they are board certified.
    Current ActiveNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

School, training and certification

4 placements

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • Ophthalmologycertified 2024 · through 2030

Residency and fellowship

  • Cole Eye Institute, Cleveland Clinic, Vitreoretinal SurgeryCLEVELAND, OHIO · 2002
  • University of Tennessee Memphis, Ophthalmic Oncology & Orbital DiseasesMEMPHIS, TENNESSEE · 2000
  • Tulane University School of Medicine, OphthalmologyNEW ORLEANS, LOUISIANA · 1999
  • Tulane University School of Medicine, TransitionalNEW ORLEANS, LOUISIANA · 1996

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$82,136

Medicare paid this office $82,136 for 319 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection of drug into eye66$40,398$84
Return visit (30+ min)268$28,300$76
Imaging of retina305$9,719$21
Measurement of corneal curvature and depth of eye61$1,476$24

Who their Medicare patients are

319 Original Medicare patients in 2024. Average age 78 · Women 61% · Also on Medicaid 18% · Health risk score 1.27. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 70% · Diabetes 34% · Coronary heart disease 24% · Chronic kidney disease 20% · Cancer 19% · Atrial fibrillation 16% · Depression 15% · Heart failure 13% · COPD 9% · Stroke 8% · Dementia 7%.

The office billed $791,326, Medicare allowed $115,226 and paid $82,136; for 1,419 services of 15 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243191,419781.27$791,326$82,136
20232971,201781.33$621,696$78,565
20223431,467781.42$602,506$89,244
20214031,677771.38$677,571$101,982
20203541,613771.38$717,090$108,153
20194241,927761.42$875,635$131,396
20184842,085761.37$950,344$143,809
20175332,296761.35$914,838$147,669
20164942,012761.28$785,746$137,094
20154882,326761.27$1,184,597$268,897
20145773,183761.25$1,680,382$482,250
20135823,166761.29$1,640,954$428,646

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 5 services

Original Medicare services billed in 2023
Injection of drug into eye63$42,975$88
Return visit (30+ min)250$25,678$81
Imaging of retina236$6,443$22
Measurement of corneal curvature and depth of eye57$1,542$26
Photography of the retina27$502$17

2022: 6 services

Original Medicare services billed in 2022
Injection of drug into eye73$47,312$81
Return visit (30+ min)300$29,732$78
Imaging of retina310$8,426$22
Measurement of corneal curvature and depth of eye54$1,482$27
Established patient complete exam of visual system22$1,310$52
Photography of the retina17$330$17

2021: 6 services

Original Medicare services billed in 2021
Injection of drug into eye88$56,029$83
Established patient complete exam of visual system246$18,863$61
Return visit (30+ min)118$11,589$86
Imaging of retina321$9,416$22
New patient complete exam of visual system33$2,578$78
Measurement of corneal curvature and depth of eye66$1,692$23

2020: 6 services

Original Medicare services billed in 2020
Injection of drug into eye82$64,162$92
Established patient complete exam of visual system303$25,492$63
Imaging of retina296$8,413$21
Measurement of corneal curvature and depth of eye60$1,583$24
New patient complete exam of visual system16$1,135$71
Injection of drug into eye11$1,067$97

2019: 5 services

Original Medicare services billed in 2019
Injection of drug into eye92$73,271$90
Established patient complete exam of visual system356$32,528$65
Imaging of retina378$11,716$22
Long return visit (40+ min)15$1,171$78
New patient complete exam of visual system11$930$85

2018: 6 services

Original Medicare services billed in 2018
Injection of drug into eye90$65,821$90
Established patient complete exam of visual system408$37,523$63
Imaging of retina440$14,178$22
New patient complete exam of visual system21$1,648$78
Long return visit (40+ min)15$1,146$76
2d ultrasound scan of eye tissue and structures12$589$35

2017: 9 services

Original Medicare services billed in 2017
Injection of drug into eye109$65,007$90
Established patient complete exam of visual system454$44,404$64
Imaging of retina473$16,006$22
New patient visit (45+ min)30$2,965$99
New patient visit (60+ min)16$2,291$143
Long return visit (40+ min)17$1,545$91
New patient complete exam of visual system18$1,545$86
Return visit (30+ min)18$1,411$67
2d ultrasound scan of eye tissue and structures13$555$40

2016: 11 services

Original Medicare services billed in 2016
Injection of drug into eye106$50,832$88
Established patient complete exam of visual system357$34,237$66
Imaging of retina376$14,140$24
Return visit (30+ min)84$4,990$55
New patient visit (60+ min)22$2,812$128
New patient visit (45+ min)21$2,036$97
Long return visit (40+ min)22$1,798$82
New patient complete exam of visual system19$1,296$68
2d ultrasound scan of eye tissue and structures22$1,242$46
Examination of eye by ophthalmoscope with retinal drawing27$944$19
Established patient problem focused exam of visual system11$778$49

2015: 16 services

Original Medicare services billed in 2015
Injection, aflibercept, 1 mg18$93,160None
Injection of drug into eye100$42,565$87
Established patient complete exam of visual system231$19,829$66
Return visit (30+ min)199$17,052$65
Imaging of retina346$15,607$25
Removal of membrane of retina with removal of internal limiting membrane of retina13$14,908$1,065
Injection of drug into eye20$7,959$98
Established patient complete exam of visual system44$6,393$107
Imaging of retina54$3,535$44
Long return visit (40+ min)35$3,459$96
Return visit (30+ min)32$2,792$87
New patient visit (60+ min)15$2,134$142
New patient visit (45+ min)17$1,479$87
Short return visit (20+ min)23$1,318$44
2d ultrasound scan of eye tissue and structures20$1,047$46
Photography of the retina16$446$22

2014: 21 services

Original Medicare services billed in 2014
Injection, aflibercept, 1 mg23$165,169None
Injection, ranibizumab, 0.1 mg13$95,863None
Injection of drug into eye97$50,617$88
Injection of drug into eye47$26,943$95
Established patient complete exam of visual system245$19,002$64
Imaging of retina365$13,096$25
Return visit (30+ min)151$11,256$64
Established patient complete exam of visual system61$9,044$110
Imaging of retina88$6,200$42
Return visit (30+ min)49$5,922$91
Unclassified biologics20$4,779None
New patient visit (45+ min)38$3,887$102
Exam of retinal blood vessels using a special camera after injection of a dye32$2,921$44
New patient visit (60+ min)13$1,944$150
Long return visit (40+ min)17$1,776$99
2d ultrasound scan of eye tissue and structures27$1,758$49
Exam of retinal blood vessels using a special camera after injection of a dye14$1,519$108
Short return visit (20+ min)29$1,501$41
Short return visit (20+ min)17$1,126$51
Examination of eye by ophthalmoscope with retinal drawing11$425$20
Photography of the retina13$355$21

2013: 22 services

Original Medicare services billed in 2013
Injection, aflibercept, 1 mg16$132,161None
Injection of drug into eye108$50,178$87
Injection of drug into eye39$19,724$95
Established patient complete exam of visual system187$16,039$65
Removal of membrane of retina with removal of internal limiting membrane of retina11$15,736$1,311
Return visit (30+ min)193$15,341$64
Imaging of retina314$13,313$25
Established patient complete exam of visual system51$8,006$114
New patient visit (60+ min)47$6,389$136
Return visit (30+ min)57$5,690$86
Imaging of retina87$5,550$43
Long return visit (40+ min)49$4,818$86
Exam of retinal blood vessels using a special camera after injection of a dye53$4,679$41
Unclassified biologics16$3,624None
New patient visit (45+ min)31$3,231$104
Long return visit (40+ min)22$2,811$128
Examination of eye by ophthalmoscope with retinal drawing84$2,712$19
Exam of retinal blood vessels using a special camera after injection of a dye20$2,653$111
2d ultrasound scan of eye tissue and structures30$1,912$44
Short return visit (20+ min)24$1,201$43
Photography of the retina22$599$21
Examination of eye by ophthalmoscope with retinal drawing16$411$26

Medicaid work

$36,550 in 2024

Medicaid paid $36,550 for 1,254 billed services this clinician did in 2024, up to 31 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Intravitreal injection of a pharmacologic agent (separate procedure)144$13,702
Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral772$11,686
Return visit (30+ min)110$6,124
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina129$2,157
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral70$1,893
Service29$989
Medicaid work by year
20241,254631$36,550
20233,242851$79,132
20222,779844$90,069
20211,289630$60,855
20201,417642$44,209
20192,0811038$119,629
20182,0371146$101,802
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Intravitreal injection of a pharmacologic agent (separate procedure)257$21,915
Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral2,145$21,639
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES165$14,326
Return visit (30+ min)209$9,608
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral252$7,518
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina181$2,981
Service18$614
Short return visit (20+ min)15$531

2022

Largest Medicaid services in 2022
Intravitreal injection of a pharmacologic agent (separate procedure)283$33,209
Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral1,895$22,673
Aflibercept injection17$13,283
Return visit (30+ min)227$9,579
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES63$4,798
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina197$3,963
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral82$2,087
Service15$477

2021

Largest Medicaid services in 2021
Intravitreal injection of a pharmacologic agent (separate procedure)296$38,476
Imaging of retina for detection or monitoring of disease; with remote physician or other qualified health care professional interpretation and report, unilateral or bilateral358$5,960
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST172$5,705
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina237$4,646
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral152$3,613
Service74$2,455

2020

Largest Medicaid services in 2020
Intravitreal injection of a pharmacologic agent (separate procedure)304$19,167
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT557$10,791
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST198$5,709
Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral170$4,758
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina158$2,812
Service30$972

2019

Largest Medicaid services in 2019
Intravitreal injection of a pharmacologic agent (separate procedure)498$43,822
Aflibercept injection56$30,631
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT532$10,892
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST290$7,721
Service206$6,999
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent121$6,461
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina235$4,481
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES55$4,448
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial60$2,744
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST28$1,430

2018

Largest Medicaid services in 2018
Intravitreal injection of a pharmacologic agent (separate procedure)225$25,916
Aflibercept injection47$21,682
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent288$12,764
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST427$11,436
Service298$10,060
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina322$6,161
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT275$4,741
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial91$4,394
OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES27$1,927
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES24$1,744
OFF/OP CNSLTJ NEW/EST MOD 4013$977

Drugs they prescribed that Part D paid

$649

Pharmacies billed $649 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 20) in 2024. Too few prescriptions to compare fairly with other clinicians.

20 generic and 0 brand-name prescriptions · $649 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Azelastine13$541$42

Year by year

Part D prescribing by year
202420None0% (0)0%$649
202318None0% (0)None$1,051
202237210% (0)30%$3,606
202153240% (0)25%$2,869
202031None0% (0)39%$1,185
201922110% (0)59%$1,418
201846250% (0)46%$2,943
201740190% (0)53%$3,826
201656250% (0)84%$6,772
201548230% (0)85%$5,361
201483400% (0)65%$6,771
201395430% (0)66%$7,646

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 1 drug

Part D drugs prescribed in 2023
Azelastine14$398$28

2022: 1 drug

Part D drugs prescribed in 2022
Azelastine15$539$36

2021: 1 drug

Part D drugs prescribed in 2021
Azelastine22$1,528$69

2017: 1 drug

Part D drugs prescribed in 2017
Pataday11$1,857$169

2016: 1 drug

Part D drugs prescribed in 2016
Pataday28$4,535$162

2015: 2 drugs

Part D drugs prescribed in 2015
Pataday13$2,555$197
Prednisolone Acetate16$827$52

2014: 3 drugs

Part D drugs prescribed in 2014
Pataday19$2,673$141
Ketorolac Tromethamine12$334$28
Latanoprost15$234$16

2013: 4 drugs

Part D drugs prescribed in 2013
Patanol11$1,926$175
Latanoprost18$295$16
Prednisolone Acetate12$290$24
Ketorolac Tromethamine11$283$26

Money from drug and device companies

$372,743 in 2025

Industry payments by year
2025532$348,000$372,743
2024535$292,070$293,341
2023514$146,674$147,032
2022214$250,125$250,170
202129$118,375$119,126
2020517$190,797$190,816
2019411$41,932$75,959

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Ocular TherapeutixDextenza$372,531
28 payments
  • Consulting · 2025-12-31 · $36,000
  • Meals for Dextenza · 2025-12-17 · $346
  • Consulting · 2025-11-30 · $36,000
  • Consulting · 2025-11-03 · $36,000
  • Meals for Dextenza · 2025-10-18 · $25
  • Meals for Dextenza · 2025-10-16 · $137
  • Meals for Dextenza · 2025-09-13 · $18
  • Meals for Dextenza · 2025-09-12 · $63
  • Meals for Dextenza · 2025-09-11 · $16
  • Meals for Dextenza · 2025-09-11 · $214
  • Consulting · 2025-09-02 · $36,000
  • Consulting · 2025-08-01 · $36,000
  • Meals for Dextenza · 2025-07-30 · $269
  • Consulting · 2025-06-29 · $36,000
  • Meals for Dextenza · 2025-06-21 · $29
  • Consulting · 2025-05-31 · $36,000
  • Meals for Dextenza · 2025-05-09 · $107
  • Consulting · 2025-04-09 · $24,000
  • Consulting · 2025-03-12 · $24,000
  • Consulting · 2025-03-05 · $24,000
  • Travel · 2025-01-31 · $3,471
  • Travel · 2025-01-31 · $19,200
  • Consulting · 2025-01-31 · $24,000
  • Meals for Dextenza · 2025-01-17 · $67
  • Meals for Dextenza · 2025-01-17 · $76
  • Meals for Dextenza · 2025-01-17 · $155
  • Meals for Dextenza · 2025-01-16 · $277
  • Meals for Dextenza · 2025-01-15 · $60
Topcon HealthcareNone$84
1 payment
  • Meals · 2025-10-18 · $84
Alcon VisionUnity$45
1 payment
  • Meals for Unity · 2025-08-02 · $45
Astellas Pharma USIzervay$42
1 payment
  • Meals for Izervay · 2025-09-11 · $42
Apellis PharmaceuticalsSyfovre$41
1 payment
  • Meals for Syfovre · 2025-10-17 · $41
See all 32 published payments
Every published payment
Ocular TherapeutixConsulting · 2025-12-31None$36,000
Ocular TherapeutixMeals · 2025-12-17Dextenza$346
Ocular TherapeutixConsulting · 2025-11-30None$36,000
Ocular TherapeutixConsulting · 2025-11-03None$36,000
Topcon HealthcareMeals · 2025-10-18None$84
Ocular TherapeutixMeals · 2025-10-18Dextenza$25
Apellis PharmaceuticalsMeals · 2025-10-17Syfovre$41
Ocular TherapeutixMeals · 2025-10-16Dextenza$137
Ocular TherapeutixMeals · 2025-09-13Dextenza$18
Ocular TherapeutixMeals · 2025-09-12Dextenza$63
Astellas Pharma USMeals · 2025-09-11Izervay$42
Ocular TherapeutixMeals · 2025-09-11Dextenza$16
Ocular TherapeutixMeals · 2025-09-11Dextenza$214
Ocular TherapeutixConsulting · 2025-09-02None$36,000
Alcon VisionMeals · 2025-08-02Unity$45
Ocular TherapeutixConsulting · 2025-08-01None$36,000
Ocular TherapeutixMeals · 2025-07-30Dextenza$269
Ocular TherapeutixConsulting · 2025-06-29None$36,000
Ocular TherapeutixMeals · 2025-06-21Dextenza$29
Ocular TherapeutixConsulting · 2025-05-31None$36,000
Ocular TherapeutixMeals · 2025-05-09Dextenza$107
Ocular TherapeutixConsulting · 2025-04-09None$24,000
Ocular TherapeutixConsulting · 2025-03-12None$24,000
Ocular TherapeutixConsulting · 2025-03-05None$24,000
Ocular TherapeutixTravel · 2025-01-31None$3,471
Ocular TherapeutixTravel · 2025-01-31None$19,200
Ocular TherapeutixConsulting · 2025-01-31None$24,000
Ocular TherapeutixMeals · 2025-01-17Dextenza$67
Ocular TherapeutixMeals · 2025-01-17Dextenza$76
Ocular TherapeutixMeals · 2025-01-17Dextenza$155
Ocular TherapeutixMeals · 2025-01-16Dextenza$277
Ocular TherapeutixMeals · 2025-01-15Dextenza$60
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $293,341

Payments by company in 2024
Ocular TherapeutixDextenza$193,271
25 payments
  • Meals for Dextenza · 2024-12-05 · $60
  • Consulting · 2024-12-02 · $12,000
  • Consulting · 2024-12-02 · $12,000
  • Meals for Dextenza · 2024-11-22 · $138
  • Meals for Dextenza · 2024-11-22 · $72
  • Consulting · 2024-11-11 · $12,000
  • Consulting · 2024-11-11 · $12,000
  • Meals for Dextenza · 2024-10-18 · $36
  • Consulting · 2024-10-02 · $6,000
  • Consulting · 2024-10-02 · $18,000
  • Consulting · 2024-09-06 · $16,800
  • Consulting · 2024-09-06 · $7,200
  • Consulting · 2024-08-01 · $2,400
  • Consulting · 2024-08-01 · $19,200
  • Consulting · 2024-08-01 · $2,400
  • Meals for Dextenza · 2024-07-18 · $440
  • Meals for Dextenza · 2024-07-16 · $82
  • Meals for Dextenza · 2024-07-16 · $144
  • Consulting · 2024-07-01 · $2,400
  • Consulting · 2024-07-01 · $21,600
  • Consulting · 2024-06-04 · $4,800
  • Consulting · 2024-06-04 · $19,200
  • Consulting · 2024-05-17 · $4,800
  • Consulting · 2024-05-17 · $19,200
  • Meals for Dextenza · 2024-05-09 · $299
Alexion PharmaceuticalsNone$90,000
5 payments
  • Consulting · 2024-02-28 · $18,000
  • Consulting · 2024-02-27 · $18,000
  • Consulting · 2024-02-05 · $18,000
  • Consulting · 2024-02-05 · $18,000
  • Consulting · 2024-02-05 · $18,000
Boehringer Ingelheim International GmbHNone$4,250
2 payments
  • Consulting · 2024-08-11 · $850
  • Consulting · 2024-05-15 · $3,400
Akebia TherapeuticsNone$3,000
1 payment
  • Consulting · 2024-10-23 · $3,000
Regeneron PharmaceuticalsEylea$2,820
2 payments
  • Consulting for Eylea · 2024-01-26 · $940
  • Consulting for Eylea · 2024-01-26 · $1,880

2023: $147,032

Payments by company in 2023
Alexion PharmaceuticalsNone$145,159
7 payments
  • Consulting · 2023-09-11 · $19,800
  • Consulting · 2023-07-14 · $21,409
  • Consulting · 2023-06-02 · $19,800
  • Consulting · 2023-05-04 · $19,800
  • Consulting · 2023-03-30 · $24,255
  • Consulting · 2023-03-09 · $20,048
  • Consulting · 2023-02-02 · $20,048
GenentechNone$1,515
1 payment
  • Consulting · 2023-12-05 · $1,515
Alcon VisionConstellation$168
3 payments
  • Meals for Constellation · 2023-10-13 · $11
  • Meals for Constellation · 2023-10-13 · $11
  • Meals for Constellation · 2023-06-03 · $147
Regeneron PharmaceuticalsEylea$110
2 payments
  • Meals for Eylea · 2023-02-21 · $90
  • Meals for Eylea · 2023-02-17 · $20
EyePoint Pharmaceuticals USYutiq$81
1 payment
  • Meals for Yutiq · 2023-04-24 · $81

2022: $250,170

Payments by company in 2022
Alexion PharmaceuticalsNone$250,125
13 payments
  • Consulting · 2022-12-01 · $20,000
  • Consulting · 2022-10-27 · $22,000
  • Consulting · 2022-09-29 · $20,000
  • Consulting · 2022-09-08 · $15,750
  • Consulting · 2022-09-08 · $12,500
  • Consulting · 2022-07-14 · $20,000
  • Consulting · 2022-06-02 · $20,000
  • Consulting · 2022-06-02 · $20,000
  • Consulting · 2022-04-21 · $20,000
  • Consulting · 2022-02-24 · $20,000
  • Consulting · 2022-02-10 · $20,000
  • Consulting · 2022-01-06 · $20,375
  • Consulting · 2022-01-06 · $19,500
Apellis PharmaceuticalsNone$45
1 payment
  • Meals · 2022-11-11 · $45

2021: $119,126

Payments by company in 2021
Alexion PharmaceuticalsNone$118,375
7 payments
  • Consulting · 2021-08-05 · $20,000
  • Consulting · 2021-06-17 · $6,500
  • Consulting · 2021-05-20 · $12,750
  • Consulting · 2021-04-15 · $16,750
  • Consulting · 2021-03-18 · $23,250
  • Consulting · 2021-02-18 · $20,500
  • Consulting · 2021-01-14 · $18,625
Alcon VisionNone$751
2 payments
  • Travel · 2021-07-31 · $481
  • Meals · 2021-07-31 · $270

2020: $190,816

Payments by company in 2020
Alexion PharmaceuticalsNone$117,375
6 payments
  • Consulting · 2020-12-17 · $20,000
  • Consulting · 2020-11-19 · $24,000
  • Consulting · 2020-10-15 · $22,625
  • Consulting · 2020-09-17 · $20,500
  • Consulting · 2020-08-13 · $18,250
  • Consulting · 2020-08-01 · $12,000
Bayer HealthCare PharmaceuticalsNon-Covered$37,855
4 payments
  • Consulting for Non-Covered · 2020-04-22 · $13,400
  • Consulting for Non-Covered · 2020-04-16 · $14,405
  • Consulting for Non-Covered · 2020-01-17 · $7,370
  • Consulting for Non-Covered · 2020-01-17 · $2,680
Regeneron PharmaceuticalsEylea$32,767
5 payments
  • Consulting for Eylea · 2020-07-10 · $5,400
  • Consulting for Eylea · 2020-06-05 · $5,610
  • Consulting for Eylea · 2020-02-07 · $18,697
  • Consulting for Eylea · 2020-02-07 · $2,550
  • Consulting for Eylea · 2020-02-07 · $510
Alcon VisionConstellation$2,800
1 payment
  • Consulting for Constellation · 2020-04-10 · $2,800
Carl Zeiss Meditec AGNone Specified$19
1 payment
  • Gift for None Specified · 2020-06-09 · $19

2019: $75,959

Payments by company in 2019
Bayer HealthCare PharmaceuticalsNon-Covered$48,959
5 payments
  • Travel for Non-Covered · 2019-11-20 · $7,186
  • Travel for Non-Covered · 2019-09-11 · $9,754
  • Travel for Non-Covered · 2019-08-31 · $7,653
  • Consulting for Non-Covered · 2019-07-19 · $15,075
  • Travel for Non-Covered · 2019-06-12 · $9,293
Regeneron PharmaceuticalsEylea$26,857
4 payments
  • Consulting for Eylea · 2019-08-22 · $4,417
  • Consulting for Eylea · 2019-07-25 · $12,750
  • Consulting for Eylea · 2019-07-10 · $3,570
  • Consulting for Eylea · 2019-07-10 · $6,120
Novartis PharmaceuticalsBeovu$77
1 payment
  • Meals for Beovu · 2019-10-10 · $77
AllerganOzurdex$66
1 payment
  • Meals for Ozurdex · 2019-11-16 · $66

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharma AG · Crth258b2301 & Crth258b2302 · 2020This clinician$106,882
Apellis Pharmaceuticals, Inc. · Study To Compare the Efficacy and Safety of Intravitreal Apl-2 Therapy With Sham Injections in Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration · 2022Their institution$42,033
Novartis Pharma AG · Crth258b2301, Crth258b2302, Crth258c2301, Crth258c2302, Crth258aus04 · 2020This clinician$25,900
Novartis Pharma AG · Crth258b2301, Crth258b2302, Crth258c2301, Crth258c2302, Crth258aus04 · 2020Their institution$25,725
Novartis Pharma AG · Crth258b2301 & Crth258b2302 · 2020Their institution$18,544
Novartis Pharma AG · Crth258a2301, Crth258a2302 · 2021This clinician$11,550
Regeneron Pharmaceuticals, Inc. · Randomized, Controlled, Multi-Center Study To Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared To Laser Photocoagulation in Patients With Retinopathy of Prematurity · 2019This clinician$2,907
Regeneron Pharmaceuticals, Inc. · Randomized, Controlled, Multi-Center Study To Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared To Laser Photocoagulation in Patients With Retinopathy of Prematurity · 2023This clinician$1,828
Regeneron Pharmaceuticals, Inc. · A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal Vegf Trap in Subjects With Neovascular Age-Related Macular Degeneration · 2019This clinician$764
F. Hoffmann-La Roche AG · Va2 Phiii · 2025This clinician$281

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1386702819
Licence
CA A78163, VA 101277785California A78163: Current · expires 2028-03-31Virginia 0101277785: Current Active
Trained
Tulane University School of Medicine, 1995
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
Mailing address
2452 Watson Ct Ste 2277, Palo Alto, CA, 94303
NPI first listed
2006-12-05
NPI last updated
2026-06-16
NPI record certified
2026-06-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305